DRL logo

assays

From Fresh Tumor to IND-Ready Data — Under One Roof

DRL's research services platform is GLP-aligned: every assay, every analysis, every validation step is designed to hold up at the IND stage.
Tell us your indication, preferred model type and we will match the right DRL product and study plan to your timeline.
Talk to scientist

What Preclinical Research Services Does DRL Offer?

Compound Screening & Drug Discovery
Measure cell viability, proliferation, and apoptosis induction.
Immune Profiling & Functional Assays
Profile TME immune cells. Assess T-cell diversity and cytokine production.
Biomarker & Protein Analysis
Evaluate cancer-specific biomarkers. Validate targets through multiplex protein analysis.
Genomic Analysis
Identify cancer-specific mutations and chromosomal rearrangements for personalized medicine.
Invasiveness & Metastasis
Evaluate the invasive potential of cancer cells to understand mechanisms of metastasis.

Compound Screening & Drug Discovery

samples

Primary Cancer Cells
3D Organoids

Applications

Develop and optimize cell-based assays for high-throughput drug screening.
Perform high-throughput screening to identify lead compounds with anticancer activity.
Validate hits through secondary assays and mechanistic studies to confirm their potential.
Discover new therapeutic candidates for cancer treatment by screening compound libraries.
Cell-based assay development
Design and optimize assays to evaluate compound effects on cell viability, proliferation, and function.
High-throughput screening of compounds of interest
Test large compound libraries for anticancer activity using automated systems.
Hit identification and validation
Confirm and characterize hits from primary screens using secondary assays and mechanistic studies.

Cell Viability & Apoptosis

samples

Primary cancer cells
3D Organoids

Applications

Screen potential anticancer compounds for cytotoxicity to identify promising therapeutic candidates.
Assess cell proliferation rates to understand the effects of treatments on cancer cell growth.
Evaluate apoptosis induction by therapeutic agents to determine their effectiveness.
Monitor metabolic activity as an indicator of cell health and viability.

assays

Cell viability assays (MTT, MTS, CellTiter Glo)
Measure cell viability and metabolic activity using colorimetric or luminescent readouts.
Apoptosis assays (Annexin V, PI staining, Cl Caspase measurement, TUNEL)
Detect and quantify apoptotic cells using flow cytometry, microscopy, or plate-based assays.
High-throughput proliferation assays (MTT, MTS)
Quantify cell proliferation rates using colorimetric assays.
Cell cycle assessment
Analyzes cell cycle distribution using flow cytometry.

Immune Profiling & Functional Assays

samples

Tumor Biopsies
Blood Samples
Primary Immune Cells

Applications

Profile immune cell populations within the tumor microenvironment to understand immune response.
Assess T-cell receptor diversity and clonality, providing insights into immune recognition of cancer.
Measure immune response to cancer therapies, such as checkpoint inhibitors.
Evaluate functional activity of immune cells, such as cytotoxicity and cytokine production, to assess immunotherapy efficacy.

assays

TCR profiling
Analyzes T-cell receptor diversity and clonality using DNA or RNA from immune cells.
Gene expression profiling
Measures the expression levels of immune-related genes using RNA extracted from immune cells or tissues.
IHC
Visualizes immune cell infiltration and protein expression in tissue sections.
Flow cytometry
Analyzes immune cell populations and their functional states using single-cell suspensions from blood or tissues.

Biomarker & Protein Analysis

samples

Tumor Biopsies
Blood Samples
Tissue Samples
Primary Cancer Cells
3D Organoids

Applications

Evaluate expression levels of cancer-specific biomarkers to identify and validate therapeutic targets.
Monitor treatment response by tracking changes in biomarker expression.
Conduct multiplex assays to detect multiple biomarkers simultaneously, improving diagnostic accuracy.

assays

qPCR (GENE IN VITRO)
Quantifies gene expression levels using RNA extracted from cells or tissues.
WESTERN BLOT (PROTEIN IN VITRO)
Detects specific proteins and assesses their expression levels using protein extracts from cell or tissue samples.
ELISA (PROTEIN IN VITRO or EX VIVO)
Measures protein concentration in various sample types, including blood and tissue extracts.
IHC/IF (PROTEIN STAINING EX VIVO)
Immunohistochemistry (IHC) and Immunofluorescence (IF) visualize protein expression in tissue sections, cells, and organoids.
Flow-cytometry
Analyzes cell surface and intracellular protein expression in single cells from blood, tissue, or cell samples.
Luminex® multiplex assay
Simultaneously measures multiple proteins in a single sample using bead-based technology.

Genomic Analysis

Advanced genomic analysis to identify cancer mutations, detect chromosomal changes, and enable personalized treatment—using PCR, NGS, and WES across tumor, blood, and FFPE samples.

samples

Tumor Biopsies
Blood Samples
FFPE Tissue Samples
Primary Cancer Cells
3D Organoids

Applications

Identify and characterize cancer-specific mutations to understand the genetic basis of different cancer types.
Detect large chromosomal rearrangements, aiding in the diagnosis and prognosis of cancers.
Develop targeted therapies by understanding genetic alterations.
Perform comprehensive genomic profiling for personalized medicine approaches.

assays

PCR (for known in-dels)
Detects specific insertions and deletions within genes.
Uses DNA extracted from tumor samples.

Invasiveness & Metastasis

samples

Primary Cancer Cells

Applications

Evaluate the invasive potential of cancer cells to understand mechanisms of metastasis.
Assess the effect of drugs on cell migration and invasion to develop anti-metastatic therapies.
Study the molecular mechanisms underlying cancer cell invasiveness and metastasis.

assays

Matrigel invasion assay
Quantifies gene expression levels using RNA extracted from cells or tissues.
Scratch migration assay
Assesses cell migration by creating a “scratch” in a cell monolayer and measuring the rate of wound closure.
DRL logo
Contract research organization, which provides solutions for pharma and diagnostics companies, including consulting, cancer models development, and various assays for drug development.
contact
28047 Dorothy Drive, #204,
Agoura Hills, CA 91301, USA
Call: +1 442-224-3375
E-mail: Info@drlus.com
Services
Biobank
Assays
LelekaBio
Support & Expertise
company
About Us
Team
Blog
Resources
Contact
©2026 DRL US. All Rights Reserved.